"Pharmaceutical Speed ​​Reading Society" National Health Commission launches special control actions for unreasonable medical examinations

[April 14, 2021 / List of medical information] The National Health Commission launched a special treatment action for irrational medical examinations; Gilead Trop-2 antibody conjugate drug added indications; Rongchang Bio-Tetacept officially launched.

[April 14, 2021 / List of medical information] Daily news about fresh medicines and medical news, Speed ​​Reading Club will pay attention to you together!

Part1 Policy Brief

Part1 policy briefing Part1 policy briefing

National Medical Insurance Administration: 24 billion prepaid funds guarantee free vaccination

National Medical Insurance Administration: 24 billion prepaid funds guarantee free vaccination

my country's new crown pneumonia vaccination is based on the principle of voluntary vaccination by individuals and free of charge by the country.

Heavy files landed nationwide! The first case of “serious” dishonesty related drugs was suspended for online trading

Heavy files landed nationwide! The first case of “serious” dishonesty related drugs was suspended for online trading

On April 12, the Zhejiang Pharmaceutical Equipment Procurement Platform issued the "Notice on the Evaluation Results of Medical Prices and Untrustworthy Levels of Recruitment and Procurement in Our Province (2021 Phase One)".

The National Health Commission launches special treatment actions for unreasonable medical examinations

The National Health Commission launches special treatment actions for unreasonable medical examinations

On April 14, the National Health Commission, the National Medical Insurance Bureau and others jointly issued a notice on the implementation of special treatment actions for unreasonable medical examinations.

National Food and Drug Administration: Guifu Dihuang Granules converted to non-prescription drugs

National Food and Drug Administration: Guifu Dihuang Granules converted to non-prescription drugs

On April 13, the State Food and Drug Administration issued an announcement stating that Guifu Dihuang Granules had been converted from prescription drugs to non-prescription drugs.

Part2 Observation

Part2 Sankei Observation Part2 Sankei Observation

Rongchang Bio-Tetaxipu is officially on sale! Hanging net price 5172 yuan / box

Rongchang Bio-Tetaxipu is officially on sale! Hanging net price 5172 yuan / box

Rongchang Biotech announced that the new dual-target biological drug “Tetazep” for the treatment of systemic lupus erythematosus has been listed in Shandong for the first time.

Yaodou.

Yaodou.

Part3 Medicine News

Part3 Medicine News Part3 Medicine News

Nuocheng Jianhua Obutinib Obtained NMPA Approval to Start Phase II Clinical Study for Treatment of Multiple Sclerosis

Nuocheng Jianhua Obutinib Obtained NMPA Approval to Start Phase II Clinical Study for Treatment of Multiple Sclerosis

Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase inhibitor obutinib for the treatment of multiple sclerosis has passed the clinical research new drug review of the State Food and Drug Administration, and has been approved to launch Phase II clinical trials in China the study.

Izcargo, a biological product that crosses the blood-brain barrier, was approved for the first time on the market

Izcargo, a biological product that crosses the blood-brain barrier, was approved for the first time on the market

A few days ago, JCR Pharmaceuticals announced that the Ministry of Health, Labour and Welfare of Japan has approved the listing of Izcargo for the treatment of mucopolysaccharidosis type II.

Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA

Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA

On April 13, the US FDA granted vTv Therapeutics' research drug TTP399 the title of breakthrough therapy for type 1 diabetes.

Gilead's Trop-2 antibody conjugate drug gains second indication

Gilead's Trop-2 antibody conjugate drug gains second indication

Today, Gilead Sciences announced that the US FDA has accelerated the approval of its Trop-2 antibody-conjugated drug Trodelvy to expand the scope of use for the treatment of patients with locally advanced or metastatic urothelial cancer.

Novartis/Roche Xolair Prefilled Syringe Receives FDA Approval

Novartis/Roche Xolair Prefilled Syringe Receives FDA Approval

On April 12, the FDA approved a supplementary biological product license application for Xolair prefilled syringes.

Huadong Medicine's polycaprolactone microsphere facial filler for injection obtained medical device registration certificate

Huadong Medicine's polycaprolactone microsphere facial filler for injection obtained medical device registration certificate

On April 13, Huadong Medicine issued an announcement stating that Sinclair, a wholly-owned subsidiary of the United Kingdom, has recently received the "Medical Device Registration Certificate" issued by the State Food and Drug Administration for injection-use polycaprolactone microsphere facial fillers.

AstraZeneca osimertinib approved in China for adjuvant treatment of patients with early-stage EGFR-mutant lung cancer

AstraZeneca osimertinib approved in China for adjuvant treatment of patients with early-stage EGFR-mutant lung cancer

On April 14th, AstraZeneca announced that the National Food and Drug Administration has formally approved the targeted drug Teresa for use in non-small cells with epidermal growth factor receptor exon 19 deletion or exon 21 substitution mutation in stage IB-IIIA For the treatment of lung cancer patients, the patient must have previously undergone surgical resection, and the doctor must decide whether to accept or not to accept adjuvant chemotherapy.

Cansino issued a statement: the new coronavirus vaccine Ad5-nCoV did not cause a thrombotic reaction

Cansino issued a statement: the new coronavirus vaccine Ad5-nCoV did not cause a thrombotic reaction

On April 14, CanSino issued a statement stating that the company had noticed some media reports about rare and severe cases of blood clots in individuals after being vaccinated with AstraZeneca's new crown vaccine and Johnson's new crown vaccine.

Zai Lab owns the rights of tumor electric field therapy in Greater China

Zai Lab owns the rights of tumor electric field therapy in Greater China

Today, Novocure announced that its tumor electric field therapy has made positive progress in a pivotal phase 3 clinical trial for the treatment of patients with non-small cell lung cancer.
This innovative treatment has been approved by the US FDA and used in combination with chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma.
In China, Zai Lab already owns the development rights of tumor electric field therapy in Greater China.
(WuXi AppTec)

Suoyuan Biotech's "first-in-class" new drug achieves overseas authorization

Suoyuan Biotech's "first-in-class" new drug achieves overseas authorization

On April 14, Suoyuan Biotech signed a global license agreement with Rumpus Therapeutics/Aytu Biopharma to develop DB102 for the treatment of rare genetic diseases such as Vascular Ehlers-Danglos Syndrome.
According to the agreement, Aytu BioPharma will be responsible for the clinical development and commercialization of DB102 for this rare disease, and will pay Suoyuan Biopharmaceuticals for the milestone and sales commission of US$100 million.
(Sina Pharmaceutical News)

Eli Lilly closes Dermira plant to transfer hyperhidrosis drug Qbrexza

Eli Lilly closes Dermira plant to transfer hyperhidrosis drug Qbrexza

A few days ago, Eli Lilly announced that it would close its Dermira plant in Menlo Park, lay off 163 employees, and intend to sell the hyperhidrosis drug Qbrexza to Journey Medical.
Eli Lilly acquired Dermira, a dermatology company, in January 2020 for a total price of approximately US$1.
1 billion, thereby obtaining FDA-approved hyperhidrosis drug assets and Lebrikizumab, as well as an emerging drug product line.
(Sina Pharmaceutical News)